Company intelligence

Dren Bio

As of October 30, 2026, Dren Bio was last valued at $1B (October 2026 funding round) and has raised at least $350M in equity across 1 sourced funding round.

Last verified Oct 30, 2026

Dren Bio at a glance

As of
Latest valuation
$1B[1]
Funding round · October 2026Derived
Equity raised
$350M[2]
Across 1 sourced roundDerived
Lead investors
Lightspeed Venture Partners[3]
Funding round · October 2026
  1. [1] Latest valuation: Pulse2, October 30, 2026
  2. [2] Equity raised: Sum of the 1 sourced equity round in the funding history below (debt, tender offers and rumored rounds excluded), October 30, 2026
  3. [3] Lead investors: Pulse2, October 30, 2026

Recent changes

  1. Oct 30, 2026Raised $350M at a $1B valuation Pulse2
  2. Oct 30, 2026First reported valuation: $1B Pulse2
  3. Oct 30, 2026New investor: 8VC Pulse2
  4. Oct 30, 2026New investor: OrbiMed Advisors Pulse2
  5. Oct 30, 2026New investor: SR One Capital Management Pulse2
Earlier changes (4)
  1. Oct 30, 2026New investor: General Catalyst Pulse2
  2. Oct 30, 2026New investor: Cormorant Asset Management Pulse2
  3. Oct 30, 2026New investor: Lightspeed Venture Partners Pulse2
  4. Oct 30, 2026Dren Bio Closes Oversubscribed $350M For Cancer Antibody Pulse story

Funding history

1 equity event · newest first · sources dated per row
DateRoundAmountValuationLead investorsSource
Oct 30, 2026Funding round$350M$1Bpost-money
WithGeneral CatalystunverifiedCormorant Asset ManagementunverifiedOrbiMed Advisorsunverified8VCunverifiedSR One Capital ManagementunverifiedJuvia GroupMirae Asset Capital Life ScienceTaiho VenturesMission BioCapital+4 more
Pulse2

Equity only. “Equity raised” above sums the rounds with a dated, linked source; rumored rounds, tender offers and secondary sales are listed but not counted, and debt financing is listed separately.

Investors

Latest Pulse

  1. Dren Bio Closes Oversubscribed $350M For Cancer AntibodyDren Bio closed an oversubscribed $350 million private financing, co-led by Juvia Group and Lightspeed Venture Partners, to advance its antibody therapy dibotatug and broader immunology pipeline toward regulators.→

Coverage Timeline

newest first
  1. Oct 30, 2026FUNDINGDren Bio Closes Oversubscribed $350M For Cancer Antibody$350M Financing→

All Coverage

Related Companies

Dren Bio FAQ

What is Dren Bio's valuation?

Dren Bio was last valued at $1B in its October 2026 funding round, according to Pulse2 (October 30, 2026).

How much has Dren Bio raised?

Dren Bio has raised at least $350M in equity across 1 sourced funding round tracked by Value Add VC. The most recent was a $350M funding round in October 2026 at a $1B post-money valuation, reported by Pulse2. Debt financing, tender offers and secondary sales are not counted.

Who invested in Dren Bio?

Lead investors in Dren Bio's sourced funding rounds include Lightspeed Venture Partners. Per round: its October 2026 funding round was led by Lightspeed Venture Partners.

Sources & methodologyshow
Where these figures come from
  • Pulse2Value Add VC data2 facts

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data ·